Menu

Blog

Feb 7, 2023

Lixte Biotechnology Holdings, Inc. Reports That Its Lead Clinical Compound, Lb-100, Can Kill Cancer Cells Through Hyper-Stimulation of Cell Proliferation Signals in Pre-Clinical Models

Posted by in category: biotech/medical

—THE STUDY ESTABLISHES A NOVEL CONCEPT OF “TUMOR SUPPRESSIVE DRUG RESISTANCE”

—THE COMBINATION OF LB-100 WITH INHIBITORS OF CELLULAR STRESS RESPONSE MODULATORS WAS HIGHLY EFFECTIVE IN KILLING CANCER CELLS IN SEVERAL PRE-CLINICAL CANCER MODELS

—RESISTANCE TO THIS THERAPY CAN RESULT IN THE LOSS OF THE ONCOGENIC PROPERTIES OF CANCER CELLS

Comments are closed.